Type 2 diabetes

Annals of Internal Medicine

Volumn 152, Issue 5, 2010, Pages

  Sandeep, Vijan ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ASPARTAME; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLIPIZIDE SR; GLUCOSE; GLULISINE; GLYBURIDE MICRONIZED; GLYCOSYLATED HEMOGLOBIN; HUMAN INSULIN MIXTURE; HUMAN REGULAR INSULIN; INSULIN; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; MIGLITOL; NETAGLINIDE; PIOGLITAZONE; PLACEBO; RAMIRIPRIL; RECOMBINANT HUMAN INSULIN; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACANTHOSIS NIGRICANS; ADULT; BLOOD GLUCOSE MONITORING; BULIMIA; CALORIC INTAKE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIET RESTRICTION; DRUG INDICATION; DRUG WITHDRAWAL; EXERCISE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; IMPOTENCE; INFECTION; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PATIENT COMPLIANCE; POLYDIPSIA; POLYURIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SYMPTOM; WEIGHT REDUCTION; FEEDING BEHAVIOR; HEALTH CARE QUALITY; KINESIOTHERAPY; MASS SCREENING; UNITED STATES;

DIABETES MELLITUS, TYPE 2; EXERCISE THERAPY; FOOD HABITS; HUMANS; HYPOGLYCEMIC AGENTS; MASS SCREENING; QUALITY OF HEALTH CARE; UNITED STATES;

EID: 77950343243     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. American Diabetes Association. Diabetes Statistics. 2007. Accessed at www.diabetes.org/diabetes-basics/diabetes-statistics/ on 20 January 2010.
2. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-1053 [PMID: 15111519]
3. American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care. 2010;33 Suppl 1:S11-61. [PMID: 20042772]
4. CDC Diabetes Cost-Effectiveness Study Group, Centers for Disease Control and Prevention. The cost-effectiveness of screening for type 2 diabetes. JAMA. 1998;280:1757-1763 [PMID: 9842951]
5. Hofer TP, Vijan S, Hayward RA. Estimating the microvascular benefits of screening for type 2 diabetes. Int J Technol Assess Health Care. 2000; 16: 822-833[PMID: 11028137]
6. U.S. Preventive Services Task Force. Screening for type 2 diabetes mellitus in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;148:846-854 [PMID: 18519930]
7. Hoerger TJ, Harris R, Hicks KA, et al. Screening for type 2 diabetes mellitus: a cost-effectiveness analysis. Ann Intern Med. 2004;140:689-699 [PMID: 15126252]
8. Tuomilehto J, Lindström J, Eriksson JG, et al; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350 [PMID: 11333990]
9. Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403. [PMID: 11832527]
10. Knowler WC, Fowler SE, Hamman RF, et al; Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374:1677-1686 [PMID: 19878986]
11. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20:537-544 [PMID: 9096977]
12. Chiasson JL, Josse RG, Gomis R, et al; STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072-2077 [PMID: 12086760]
13. Gerstein HC, Yusuf S, Bosch J, et al; DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368:1096-1105 [PMID: 16997664]
14. 1c for the Diagnosis of Diabetes. Accessed at www.aace.com/pub/pdf/guidelines/AACEpositionA1cfeb2010.pdf on 4 February 2010.
15. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-853 [PMID: 9742976]
16. Thomas DE, Elliott EJ, Naughton GA. Exercise for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2006;3:CD002968. [PMID: 16855995]
17. Weischen LM, Bloemendal E, Nijpels G, et al. Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin. Cochrane Database Syst Rev. 2005; 18: CD0050060. [PMID 15846742]
18. Holman RR, Paul SK, Bethel MA, et al. Long-term follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589 [PMID: 18784090].
19. Gerstein HC, Miller ME, Byington RP, et al. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-2559 [PMID: 18539917]
20. Duckworth W, Abraira C, Moritz T, et al; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129-139 [PMID: 19092145]
21. Patel A, MacMahon S, Chalmers J, et al; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-2572 [PMID: 18539916]
22. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13 Suppl 1:1-68. [PMID: 17613449]
23. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865 [PMID: 9742977]
24. Yki-Järvinen H, Kauppila M, Kujansuu E, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1992;327:1426-1433 [PMID: 1406860]
25. Buse JB, Wolffenbuttel BH, Herman WH, et al. DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care. 2009;32:1007-1013 [PMID: 19336625]
26. Hayward RA, Manning WG, Kaplan SH, et al. Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization. JAMA. 1997;278:1663-1669 [PMID: 9388085]
27. Yki-Järvinen H, Ryysy L, Nikkilä K, et al. Comparison of bed-time insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1999;130:389-396 [PMID: 10068412]
28. Sheffield CA, Kane MP, Busch RS, et al. Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus. Endocr Pract. 2008;14:285-292 [PMID: 18463034]
29. Yoon NM, Cavaghan MK, Brunelle RL, et al. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Clin Ther. 2009;31:1511-1523 [PMID: 19695400]
30. Vijan S, Hayward RA. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med. 2003;138:593-602. [PMID: 12667032]
31. Snow V, Weiss KB, Mottur-Wilson C; Clinical Efficacy Subcommittee of the American College of Physicians. The evidence base for tight blood pressure control in the management of type 2 diabetes mellitus. Ann Intern Med 2003; 138: 587-592[PMID: 12667031]
32. Holman RR, Paul SK, Bethel MA, et al. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med. 2008;359:1565-1576 [PMID: 18784091]
33. Vijan S, Hayward RA; American College of Physicians. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med. 2004;140:650-658 [PMID: 15096337]
34. Snow V, Aronson MD, Hornbake ER, et al; Clinical Efficacy Subcommittee of the American College of Physicians. Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2004; 140: 644-649 [PMID: 15096336]
35. LaRosa JC, Grundy SM, Waters DD, et al; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435 [PMID: 15755765]
36. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350: 1495-1504 [PMID: 15007110]
37. Belch J, MacCuish A, Campbell I, et al; Prevention of Progression of Arterial Disease and Diabetes Study Group. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840. [PMID: 18927173]
38. Vijan S, Hofer TP, Hayward RA. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA. 2000;283:889-896 [PMID: 10685713] (Pubitemid 30102129)
39. Qaseem A, Vijan S, Snow V, et al; Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Glycemic control and type 2 diabetes mellitus: the optimal hemoglobin A1c targets. A guidance statement from the American College of Physicians. Ann Intern Med. 2007;147:417-422 [PMID: 17876024